RxDoctor Payments Data

Sahar Janjua, MD

Rheumatology · Dover, NHNPI 1427312792

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by GSK at 24.9% of the total. Reporting peaked in 2019 at $389 and has fallen 95.9% since, to $16 in 2022.

$536in general payments, 2019–2025

Across 33 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$134
  • Novartis$75
  • Lilly USA, LLC$70
  • Actelion Pharmaceuticals US, Inc.$48
  • Gilead$37
  • Pfizer$32
  • plus $141 from 8 others

What the payments were for

  • Food & beverage$536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$536 in reported general payments places this provider in the 55th percentile of 48 rheumatology providers in New Hampshire.

See all rheumatology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$26,373
Medicare patients
161
Services billed
249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab49$397,394
Enbrel SureclickEtanercept39$280,824
Orencia ClickjectAbatacept45$252,435
Taltz AutoinjectorIxekizumab18$211,246
RinvoqUpadacitinib25$157,415
Cosentyx Sensoready (2 Pens)Secukinumab17$120,947
Cosentyx Sensoready PenSecukinumab15$119,008
EnbrelEtanercept20$104,797
Xeljanz XrTofacitinib Citrate16$90,705
OtezlaApremilast17$81,201
XeljanzTofacitinib Citrate11$49,472
Hydroxychloroquine Sulfate88$3,037
MethotrexateMethotrexate Sodium89$1,618
Celecoxib41$1,251
Prednisone165$1,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$27$185,99937 claims
AbbVieRinvoq$17$157,41525 claims
PfizerXeljanz$32$49,47211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 48 rheumatology providers in New Hampshire.

Other rheumatology in Dover

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →